Q2 EPS Estimates for CytomX Therapeutics Cut by Wedbush

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Research analysts at Wedbush decreased their Q2 2025 earnings estimates for CytomX Therapeutics in a research report issued on Monday, May 12th. Wedbush analyst R. Driscoll now forecasts that the biotechnology company will post earnings of ($0.14) per share for the quarter, down from their prior forecast of $0.13. Wedbush currently has a "Outperform" rating and a $6.00 target price on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.05) per share. Wedbush also issued estimates for CytomX Therapeutics' Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.70) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.67) EPS and FY2029 earnings at $0.02 EPS.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.09. The firm had revenue of $50.92 million for the quarter, compared to analyst estimates of $35.42 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same period in the previous year, the company earned $0.17 earnings per share.

Other equities research analysts have also issued reports about the stock. Piper Sandler initiated coverage on shares of CytomX Therapeutics in a report on Monday, April 14th. They set an "overweight" rating and a $2.50 price objective on the stock. StockNews.com raised shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a report on Friday, March 7th.

CytomX Therapeutics Price Performance

Shares of CTMX opened at $2.50 on Wednesday. The firm has a market capitalization of $201.55 million, a PE ratio of 14.71 and a beta of 1.11. CytomX Therapeutics has a 1-year low of $0.40 and a 1-year high of $2.55. The company's fifty day moving average price is $0.73 and its 200-day moving average price is $0.87.

Institutional Investors Weigh In On CytomX Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in CytomX Therapeutics in the first quarter valued at $62,000. Miller Financial Services LLC boosted its holdings in CytomX Therapeutics by 104.0% in the first quarter. Miller Financial Services LLC now owns 51,000 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 26,000 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in CytomX Therapeutics by 18.6% in the first quarter. Assenagon Asset Management S.A. now owns 711,454 shares of the biotechnology company's stock valued at $452,000 after purchasing an additional 111,604 shares during the last quarter. Formidable Asset Management LLC boosted its holdings in CytomX Therapeutics by 55.5% in the fourth quarter. Formidable Asset Management LLC now owns 382,529 shares of the biotechnology company's stock valued at $394,000 after purchasing an additional 136,528 shares during the last quarter. Finally, Velan Capital Investment Management LP purchased a new stake in shares of CytomX Therapeutics during the 4th quarter worth about $36,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.